Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Accelerate Diagnostics reports Q1 losses but shows growth potential

Accelerate Diagnostics showcased growth potential with customer acquisitions, Wave program progress, and strategic partnerships, despite facing cost management challenges.
The company's focus on innovation, customer engagement, and operational efficiency positions it for market expansion and technology advancement in the diagnostics sector.
Addressing expense control, successful commercialization of new programs, and sustaining growth momentum are key focus areas for Accelerate Diagnostics to drive profitability.

Accelerate Diagnostics reports Q3 milestones amidst financial challenges

Accelerate Diagnostics demonstrated financial performance with notable milestones achieved in Q3 2024.
While facing challenges in managing cash burn and addressing analyst inquiries, the company showcased strengths in commercial progress and innovation.
Opportunities for growth and market leadership exist through leveraging recent FDA clearances and expanding into new markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President & Director Steve Reichling - CFO Conference Call Participants Andrew Brackmann - William Blair & Company Connor Stevenson - Craig-Hallum Operator Good afternoon, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2022 Earnings Call. [Operator Instructions].

Accelerate Diagnostics, Inc. (AXDX) Q3 2022 Earnings Call Transcript

TUCSON, Ariz. , Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022.

Accelerate Diagnostics Reports Third Quarter 2022 Financial Results

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate" or the "Company") (NASDAQ: AXDX).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ: AXDX) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

Los Angeles, California--(Newsfile Corp. - October 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate Diagnostics" or "the Company") (NASDAQ: AXDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R.

The Law Offices of Frank R. Cruz Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - October 26, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost money in their Accelerate Diagnostics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/axdx.What is this all about?After the market closed on October 21, 2022, Accelerate Diagnostics, Inc. disclosed receiving a request from the U.S.

Accelerate Diagnostics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate Diagnostics" or "the Company") (NASDAQ: AXDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Oct. 26, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) resulting from allegations that Accelerate Diagnostics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Accelerate Diagnostics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Accelerate Diagnostics, Inc. Investors to Inquire About Securities Class Action Investigation - AXDX

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C.

ACCELERATE DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Accelerate Diagnostics, Inc. on Behalf of Accelerate Diagnostics Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $AXDX #AXDX--The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) resulting from allegations that Accelerate Diagnostics may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Accelerate Diagnostics, Inc. Investors to Inquire About Securities Class Action Investigation – AXDX

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

TUCSON, Ariz. , Oct. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2022 third quarter results

TUCSON, Ariz. , Aug. 18, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share.

Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock

TUCSON, Ariz. , Aug. 17, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced that it has commenced an underwritten public offering of shares of its common stock.

Accelerate Diagnostics Announces Proposed Public Offering of Common Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President and Chief Executive Officer Steve Reichling - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Second Quarter 2022 Earnings Call. All participants will be in listen-only mode.

Accelerate Diagnostics, Inc.'s (AXDX) CEO Jack Phillips on Q2 2022 Results - Earnings Call Transcript

TUCSON, Ariz. , Aug. 15, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.

Accelerate Diagnostics Reports Second Quarter 2022 Financial Results

Becton, Dickinson and Co.

Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide FRANKLIN LAKES, N.J. and TUCSON, Ariz.

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

TUCSON, Ariz. , July 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2022 second quarter results

- Commercialization of the Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial identification (ID) for positive blood cultures across the large installed base of MALDI system users. - The Accelerate Arc system can cut hours of wait time, eliminate laborious hands-on sample prep and offer significant cost savings for healthcare facilities compared to current methods.

Accelerate Diagnostics announces commercialization in Europe of its Accelerate Arc™ system having completed IVDR registration

JanOne Inc

Transocean

Can these penny stocks make gains this month? The post Best Penny Stocks to Buy Now?

Best Penny Stocks to Buy Now? 3 to Watch This Week

TUCSON, Ariz. , May 23, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 7, 2022, at 10:00 AM Central Time.

Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Laura Pierson – Investor Relations Jack Phillips – Chief Executive Officer Steve Reichling – Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics, Inc. 2022 First Quarter Results Conference Call. All participants will be in listen-only mode.

News for Accelerate Diagnostics Stock (AXDX)